Option chain shows key data for Moleculin Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Moleculin Biotech.

Moleculin Biotech (NASDAQ:MBRX) Stock, Option Chain

Moleculin Biotech

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

nyse shutter

Analyst Color

Asia

Earnings

Earnings Beats

Earnings Misses

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

News

Regulations

Bonds

Broad U.S. Equity ETFs

Emerging Markets

Eurozone

Futures

Commodities

Forex

Economics

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

General

ABNB

BLAC

ESNT

MBRX

MRNA

MYNA

NVDA

TSLA

U.S. stock futures traded close to the flatline on Friday after Tuesday&#39;s rally. Futures of all four benchmark indices were slightly lower.

US Stocks Set For A Volatile Start: Analyst Dismisses Chances Of 20%+ S&amp;P 500 Gain For Third Year In A Row, But Says &#39;Investors Should Be Optimistic&#39;

airbnb shutter

BSLK

CNSP

FFIE

INFA

JRSH

PCLA

SLSR

STAI

STVN

VRPX

ZCAR

Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

Movers

Trading Ideas

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in late 2025, with another in 2026.

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Biotech Inc

Press Releases

"Signal Advance, Inc. (OTC: SIGL) Achieves Technology Milestone with Revolutionary Next-Gen Signal Protection – More Stocks Inside"

Small Cap

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

BNZI

CSDX

GTBP

SIGL

SKYX

SONN

Abpro Hldgs

ABVC BioPharma

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

Equillium

Ernexa Therapeutics

GlycoMimetics

Geovax Labs

Imunon

IN8bio

Kairos Pharma

Leap Therapeutics

MEI Pharma

Marker Therapeutics

NextCure

BiomX

Polyrizon

Portage Biotech

SAB Biotherapeutics

Synlogic

Unity Biotechnology

Maxim Group

HC Wainwright & Co.

Roth MKM

Oppenheimer

Comments

Moleculin Biotech

Moleculin Biotech (MBRX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell